Compare Bill.com Holdings Inc (BILL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs ResMed Inc. — how do they compare? Bill.com Holdings Inc trades at $48.19 (market cap $4.93B), while ResMed Inc. trades at $224.93 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 6.6× Bill.com Holdings Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | RMD | |
|---|---|---|
Market Cap | $4.93B | $32.61B |
Sector | Technology | Health |
52-Week High | $56.32 | $293.73 |
52-Week Low | $31.96 | $182.82 |
Enterprise Value | $4.64B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $49.26, up 2.65% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth has accelerated from $642M in 2022 to $1.46B in 2025, with the company achieving positive net income for the first time. Recent leadership changes and operational efficiency initiatives, including a 30% workforce reduction, position the company for improved profitability.
The outlook remains positive with 56% analyst buy ratings and a consensus price target of $45.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 213.91) and intense fintech competition. Upside catalysts include continued SMB adoption and AI-driven automation growth, while execution risks and market volatility present challenges for investors seeking exposure to the financial operations software sector.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
